These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 32817705)

  • 1. Rapid drug increase and early onset of levodopa-induced dyskinesia in Parkinson's disease.
    Hong JY; Sunwoo MK; Yoon JH; Kang SY; Sohn YH; Lee PH; Kim SH
    PLoS One; 2020; 15(8):e0237472. PubMed ID: 32817705
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The relationship between the phenotype of Parkinson's disease and levodopa-induced dyskinesia.
    Zhang YH; Tang BS; Song CY; Xu Q; Lou MX; Liu ZH; Yu RH; Yan XX; Guo JF
    Neurosci Lett; 2013 Nov; 556():109-12. PubMed ID: 24135335
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gender effect on time to levodopa-induced dyskinesias.
    Hassin-Baer S; Molchadski I; Cohen OS; Nitzan Z; Efrati L; Tunkel O; Kozlova E; Korczyn AD
    J Neurol; 2011 Nov; 258(11):2048-53. PubMed ID: 21533825
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Profile of levodopa-induced dyskinesia in patients of Parkinson's disease: a record based study.
    Choudhury S; Pradhan R; Paul P; Das M; Gupta A; Ghosh P; Chatterjee S
    Neurol Res; 2014 Sep; 36(9):841-6. PubMed ID: 24601722
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Levodopa-induced dyskinesia in Parkinson's disease: still no proof? A meta-analysis.
    Giannakis A; Chondrogiorgi M; Tsironis C; Tatsioni A; Konitsiotis S
    J Neural Transm (Vienna); 2018 Sep; 125(9):1341-1349. PubMed ID: 29352351
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment patterns and associated costs with Parkinson's disease levodopa induced dyskinesia.
    Suh DC; Pahwa R; Mallya U
    J Neurol Sci; 2012 Aug; 319(1-2):24-31. PubMed ID: 22664154
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Does the Side Onset of Parkinson's Disease Influence the Time to Develop Levodopa-Induced Dyskinesia?
    Chung SJ; Yoo HS; Lee HS; Lee PH; Sohn YH
    J Parkinsons Dis; 2019; 9(1):241-247. PubMed ID: 30741690
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cerebrospinal fluid levels of catecholamines and its metabolites in Parkinson's disease: effect of l-DOPA treatment and changes in levodopa-induced dyskinesia.
    Andersen AD; Blaabjerg M; Binzer M; Kamal A; Thagesen H; Kjaer TW; Stenager E; Gramsbergen JBP
    J Neurochem; 2017 May; 141(4):614-625. PubMed ID: 28244186
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Force overflow and levodopa-induced dyskinesias in Parkinson's disease.
    Wenzelburger R; Zhang BR; Pohle S; Klebe S; Lorenz D; Herzog J; Wilms H; Deuschl G; Krack P
    Brain; 2002 Apr; 125(Pt 4):871-9. PubMed ID: 11912119
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Does Late Levodopa Administration Delay the Development of Dyskinesia in Patients with De Novo Parkinson's Disease?
    Chung SJ; Yoo HS; Lee HS; Jeong HE; Kim SJ; Oh JS; Kim JS; Sohn YH; Lee PH
    CNS Drugs; 2018 Oct; 32(10):971-979. PubMed ID: 30027399
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factors predictive of the development of Levodopa-induced dyskinesia and wearing-off in Parkinson's disease.
    Warren Olanow C; Kieburtz K; Rascol O; Poewe W; Schapira AH; Emre M; Nissinen H; Leinonen M; Stocchi F;
    Mov Disord; 2013 Jul; 28(8):1064-71. PubMed ID: 23630119
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cerebellar connectivity in Parkinson's disease with levodopa-induced dyskinesia.
    Yoo HS; Choi YH; Chung SJ; Lee YH; Ye BS; Sohn YH; Lee JM; Lee PH
    Ann Clin Transl Neurol; 2019 Nov; 6(11):2251-2260. PubMed ID: 31643140
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A hospital-based study: risk factors in development of motor complications in 555 Parkinson's patients on levodopa therapy.
    Benbir G; Ozekmekçi S; Apaydin H; Delil S; Erginöz E
    Clin Neurol Neurosurg; 2006 Dec; 108(8):726-32. PubMed ID: 16564615
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of sigma-receptors in levodopa-induced dyskinesia in patients with advanced Parkinson disease: a positron emission tomography study.
    Nimura T; Ando T; Yamaguchi K; Nakajima T; Shirane R; Itoh M; Tominaga T
    J Neurosurg; 2004 Apr; 100(4):606-10. PubMed ID: 15070112
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Levodopa-induced dyskinesia in Parkinson's disease: epidemiology, etiology, and treatment.
    Zesiewicz TA; Sullivan KL; Hauser RA
    Curr Neurol Neurosci Rep; 2007 Jul; 7(4):302-10. PubMed ID: 17618536
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Levodopa-dyskinesia incidence by age of Parkinson's disease onset.
    Kumar N; Van Gerpen JA; Bower JH; Ahlskog JE
    Mov Disord; 2005 Mar; 20(3):342-4. PubMed ID: 15580606
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Age at onset influences neurodegenerative processes underlying PD with levodopa-induced dyskinesias.
    Cerasa A; Salsone M; Morelli M; Pugliese P; Arabia G; Gioia CM; Novellino F; Quattrone A
    Parkinsonism Relat Disord; 2013 Oct; 19(10):883-8. PubMed ID: 23769805
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of levodopa dose and magnitude of dopamine depletion as risk factors for levodopa-induced dyskinesia in a rat model of Parkinson's disease.
    Putterman DB; Munhall AC; Kozell LB; Belknap JK; Johnson SW
    J Pharmacol Exp Ther; 2007 Oct; 323(1):277-84. PubMed ID: 17660384
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Paradoxical facilitation after depotentiation protocol can precede dyskinesia onset in early Parkinson's disease.
    Lago-Rodriguez A; Ponzo V; Jenkinson N; Benitez-Rivero S; Del-Olmo MF; Hu M; Koch G; Cheeran B
    Exp Brain Res; 2016 Dec; 234(12):3659-3667. PubMed ID: 27566172
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk thresholds of levodopa dose for dyskinesia in Chinese patients with Parkinson's disease: a pilot study.
    Liu G; Chen H; Su D; Wang D; Zhang M; Wang X; Wang Z; Yang Y; Jiang Y; Ma H; Feng T
    Neurol Sci; 2020 Jan; 41(1):111-118. PubMed ID: 31446577
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.